Amgen Chooses To Settle In US Soliris IPR Tussle

Victory Could Have Led To 2022 Market Entry

 
• By Dean Rudge
  
2025_Dial
A successful IPR challenge could have led Amgen to potential market entry in 2022 or 2023 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business